Mounjaro vs Ozempic: Why Many Doctors Now Prefer Tirzepatide — and Who It's Actually For
Tirzepatide (Mounjaro) consistently outperforms semaglutide on weight loss in head-to-head trials. Here's why a growing number of doctors lead with it, why it still costs more, and how to know which one is right for you.
ALTRcare Medical Team
Clinical Editorial
If you've started researching weight-loss medication in India, you've probably noticed something: some doctors talk about Ozempic, others insist on Mounjaro, and the prices are very different. There's a real clinical reason behind this — not just marketing. Here's the honest version.
They're not the same kind of drug
Ozempic and Wegovy contain semaglutide, which acts on a single hunger pathway (GLP-1). Mounjaro contains tirzepatide, which acts on two pathways at once (GLP-1 and GIP). That second mechanism is the whole story — it's why tirzepatide tends to produce more weight loss for many people.
In the head-to-head and landmark trials (STEP for semaglutide, SURMOUNT for tirzepatide), tirzepatide generally delivered greater average weight loss. That's why a growing number of doctors now lead with it, especially for people who need to lose a significant amount of weight.
Why some doctors prescribe only Mounjaro
Several experienced doctors have moved to prescribing tirzepatide first. Their reasoning usually comes down to three things:
- Stronger average results — more of their patients hit meaningful weight loss, and faster.
- Often better tolerated at target effect — some patients get more result per unit of side effect.
- Fewer 'plateau' disappointments — the dual mechanism can keep working where a single pathway stalls.
A fair caveat
A single clinic's experience is real-world signal, but it isn't the same as population trial data. Tirzepatide being stronger on average doesn't make semaglutide ineffective — it works very well for a great many people. The right answer is per-patient, not one-size-fits-all.
So why is Mounjaro still pricier?
Three honest reasons. First, it's newer — less competition and fewer generic equivalents in the market so far. Second, the dual-agonist molecule is more complex to manufacture than a single-pathway drug. Third, demand — as results spread by word of mouth, the premium product commands a premium price. As more tirzepatide options enter the Indian market, expect the gap to narrow over time, the same way it did for semaglutide.
Not sure which one fits you?
Take the 2-minute assessment. A doctor reviews your weight, goals, and history before recommending semaglutide or tirzepatide — never the other way around.
Who tirzepatide (Mounjaro) is genuinely better for
- People with a larger amount to lose (20+ kg) who want the strongest available option.
- People who plateaued or under-responded on semaglutide and need a different mechanism.
- People with significant insulin resistance or type 2 diabetes, where the dual action can help metabolically.
- People who value maximum result and are comfortable with the higher cost.
Who semaglutide is still a great choice for
- People with a moderate goal (5–15 kg) where semaglutide's results are more than enough.
- People who are cost-conscious — it delivers excellent results at a meaningfully lower price.
- People starting out who want a gentler, well-established first step before considering anything stronger.
- People for whom supply and consistency matter — it's the most widely available option.
The honest bottom line
Tirzepatide is, on average, the more powerful drug — and for the right patient it's worth the premium. But 'most powerful' and 'right for you' aren't always the same word. A good doctor matches the molecule to you, not to a price tag.
Key takeaways
- Tirzepatide (Mounjaro) targets two hunger pathways; semaglutide (Ozempic) targets one.
- In trials, tirzepatide generally produces more weight loss on average.
- Many doctors now lead with tirzepatide, especially for larger weight-loss goals.
- It costs more because it's newer, more complex to make, and in high demand.
- Semaglutide is still an excellent, lower-cost choice for moderate goals.
- The right drug is a per-patient decision a doctor should make with you.
Want a doctor's view on which is right for you?
Message our care team. We'll talk through your goals and history before recommending anything.
Frequently asked questions
Is Mounjaro better than Ozempic?
On average, tirzepatide (Mounjaro) produces more weight loss than semaglutide (Ozempic) in clinical trials, because it targets two hunger pathways instead of one. But semaglutide remains highly effective and is the better choice for many people depending on their goal, budget, and tolerance. It's a per-patient decision.
Why do some doctors only prescribe Mounjaro?
Some doctors lead with tirzepatide because more of their patients reach meaningful weight loss and it can keep working where a single-pathway drug plateaus. This is real-world preference, but semaglutide is still appropriate and effective for many patients.
Why is Mounjaro more expensive than Ozempic in India?
Tirzepatide is newer, more complex to manufacture as a dual-agonist molecule, and in high demand. As more options enter the Indian market, the price gap is expected to narrow over time.
Can I switch from semaglutide to tirzepatide?
Many people who plateau or under-respond on semaglutide switch to tirzepatide under medical supervision. Any switch should be planned and dosed by a doctor, not done on your own.
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed — no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
